Drug combinations with the potential to interact among cancer patients [1]

Supportive Care in Cancer

Volumn 15, Issue 9, 2007, Pages 1113-1114

  Riechelmann, Rachel P ^a  

^a NONE   (Brazil)

Author keywords

CYP3A4; Drug interactions; Oncology

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; WARFARIN;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL PRACTICE; HUMAN; LETTER; ONCOLOGY; PRIORITY JOURNAL;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS;

EID: 34548317386     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0274-3     Document Type: Letter

References (6)

1. Haddad A, Davis M, Lungman R (2007) The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 15:251-257
2. Riechelmann RP, Saad ED (2006) A systematic review on drug interactions in oncology. Cancer Investig 24:704-712
3. Riechelmann RP, Krzyzanowska MK, O'Carroll A et al (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer
4. Riechelmann RP, Moreira F, Smaletz O et al (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56:286-290
5. Riechelmann RP, Tannock IF, Wang L et al (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592-600
6. Norton PG, Baker GR (2007) Patient safety in cancer care: a time for action. J Natl Cancer Inst 99:579-580